445 related articles for article (PubMed ID: 12618684)
1. The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions.
Sugimoto K; Hofmann LV; Razavi MK; Kee ST; Sze DY; Dake MD; Semba CP
J Vasc Surg; 2003 Mar; 37(3):512-7. PubMed ID: 12618684
[TBL] [Abstract][Full Text] [Related]
2. Comparison of urokinase, alteplase, and reteplase for catheter-directed thrombolysis of deep venous thrombosis.
Grunwald MR; Hofmann LV
J Vasc Interv Radiol; 2004 Apr; 15(4):347-52. PubMed ID: 15064337
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of limited-dose tissue plasminogen activator in acute vascular occlusion.
Shortell CK; Queiroz R; Johansson M; Waldman D; Illig KA; Ouriel K; Green RM
J Vasc Surg; 2001 Nov; 34(5):854-9. PubMed ID: 11700486
[TBL] [Abstract][Full Text] [Related]
4. Clinical and economic outcomes in thrombolytic treatment of peripheral arterial occlusive disease and deep venous thrombosis.
Ouriel K; Kaul AF; Leonard MC
J Vasc Surg; 2004 Nov; 40(5):971-7. PubMed ID: 15557913
[TBL] [Abstract][Full Text] [Related]
5. Safety of catheter-directed thrombolysis for deep venous thrombosis in cancer patients.
Kim HS; Preece SR; Black JH; Pham LD; Streiff MB
J Vasc Surg; 2008 Feb; 47(2):388-94. PubMed ID: 18241762
[TBL] [Abstract][Full Text] [Related]
6. Intraarterial catheter-directed thrombolysis: urokinase versus tissue plasminogen activator.
Cinà CS; Goh RH; Chan J; Kenny B; Evans G; Rawlinson J; Gill G
Ann Vasc Surg; 1999 Nov; 13(6):571-5. PubMed ID: 10541608
[TBL] [Abstract][Full Text] [Related]
7. Ultrasound-accelerated thrombolysis in arterial and venous peripheral occlusions: fibrinogen level effects.
Raabe RD
J Vasc Interv Radiol; 2010 Aug; 21(8):1165-72. PubMed ID: 20656221
[TBL] [Abstract][Full Text] [Related]
8. Catheter-directed thrombolysis with percutaneous rheolytic thrombectomy versus thrombolysis alone in upper and lower extremity deep vein thrombosis.
Kim HS; Patra A; Paxton BE; Khan J; Streiff MB
Cardiovasc Intervent Radiol; 2006; 29(6):1003-7. PubMed ID: 16967220
[TBL] [Abstract][Full Text] [Related]
9. Safety of thrombolytic therapy with urokinase or recombinant tissue plasminogen activator for peripheral arterial occlusion: a comprehensive compilation of published work.
Ouriel K; Kandarpa K
J Endovasc Ther; 2004 Aug; 11(4):436-46. PubMed ID: 15298504
[TBL] [Abstract][Full Text] [Related]
10. The association of periprocedural hypertension and adverse outcomes in patients undergoing catheter-directed thrombolysis.
Agle SC; McNally MM; Powell CS; Bogey WM; Parker FM; Stoner MC
Ann Vasc Surg; 2010 Jul; 24(5):609-14. PubMed ID: 20413257
[TBL] [Abstract][Full Text] [Related]
11. Catheter-directed thrombolysis of proximal lower extremity deep vein thrombosis: a prospective trial with venographic and clinical follow-up.
Manninen H; Juutilainen A; Kaukanen E; Lehto S
Eur J Radiol; 2012 Jun; 81(6):1197-202. PubMed ID: 21498014
[TBL] [Abstract][Full Text] [Related]
12. Fibrinogen level as a surrogate for the outcome of thrombolytic therapy using tissue plasminogen activator for acute lower extremity intravascular thrombosis.
Skeik N; Gits CC; Ehrenwald E; Cragg AH
Vasc Endovascular Surg; 2013 Oct; 47(7):519-23. PubMed ID: 23899656
[TBL] [Abstract][Full Text] [Related]
13. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
Collen D; Stassen JM; De Cock F
Thromb Haemost; 1987 Oct; 58(3):943-6. PubMed ID: 3124288
[TBL] [Abstract][Full Text] [Related]
14. Adjunctive percutaneous mechanical thrombectomy for lower-extremity deep vein thrombosis: clinical and economic outcomes.
Kim HS; Patra A; Paxton BE; Khan J; Streiff MB
J Vasc Interv Radiol; 2006 Jul; 17(7):1099-104. PubMed ID: 16868161
[TBL] [Abstract][Full Text] [Related]
15. Regarding "The safety, efficacy and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions".
Manfredini R; Boari B; Gallerani M; Portaluppi F; Mehta RH
J Vasc Surg; 2003 Aug; 38(2):411-2. PubMed ID: 12894792
[No Abstract] [Full Text] [Related]
16. Catheter-directed thrombolysis for iliofemoral deep venous thrombosis improves health-related quality of life.
Comerota AJ; Throm RC; Mathias SD; Haughton S; Mewissen M
J Vasc Surg; 2000 Jul; 32(1):130-7. PubMed ID: 10876214
[TBL] [Abstract][Full Text] [Related]
17. [Catheter directed thrombolysis for early left lower extremity deep venous thrombosis without vena cava filters protection].
Xiao L; Gong KM; Wang KH; Lü YJ; Chen ZS; Ouyang YM; Ling P; Long YX; Li LH
Zhonghua Wai Ke Za Zhi; 2012 Jan; 50(1):15-8. PubMed ID: 22490283
[TBL] [Abstract][Full Text] [Related]
18. Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter-directed peripheral arterial and venous thrombolysis.
Ouriel K; Gray B; Clair DG; Olin J
J Vasc Interv Radiol; 2000 Mar; 11(3):295-8. PubMed ID: 10735422
[TBL] [Abstract][Full Text] [Related]
19. Comparison of streptokinase and urokinase in local thrombolysis of peripheral arterial occlusions for lower limb salvage.
Dubé M; Soulez G; Thérasse E; Cartier P; Blair JF; Roy P; Robillard P; Bruneau L; Van Nguyen P; Cusson JR
J Vasc Interv Radiol; 1996; 7(4):587-93. PubMed ID: 8855542
[TBL] [Abstract][Full Text] [Related]
20. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
